Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ILK | Q13418 | 3/20 | 0.55 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5759036 | 0.79 | ILK (0.53) | ILKSSTR5HRH3GAAAPP | |
| SCHEMBL5756793 | 0.79 | ILK (0.52) | ILKSSTR5HRH3 | |
| SCHEMBL5756434 | 0.79 | APP (0.55) | ILKAPP | |
| SCHEMBL5755215 | 0.79 | MAPK1 (0.52) | HCRTR1HCRTR2GAA | |
| SCHEMBL5757642 | 0.78 | APP (0.52) | ILKAPP | |
| SCHEMBL5757115 | 0.77 | ILK (0.51) | ILKHRH3GAA | |
| SCHEMBL5756078 | 0.75 | KDM4E (0.55) | ILKHCRTR1GAA | |
| SCHEMBL5755158 | 0.74 | ILK (0.51) | ILKHRH3APP | |
| SCHEMBL5756448 | 0.73 | ILK (0.52) | ILKHRH3 | |
| SCHEMBL5756935 | 0.72 | ILK (0.51) | ILKHRH3GAAAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539723-B1 | NOVEL USE OF BENZOTHIAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-05-24 | — | — | EP | claimed |
| US-20060106015-A1 | Novel use of benzothiazole derivatives | ASTRAZENECA (SE) | 2006-05-18 | — | — | US | claimed |
| EP-1539723-A1 | NOVEL USE OF BENZOTHIAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | claimed |
| WO-2004016600-A1 | NOVEL USE OF BENZOTHIAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | claimed |
| EP-1539723-B1 | NOVEL USE OF BENZOTHIAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-05-24 | — | — | EP | disclosed |
| US-20060106015-A1 | Novel use of benzothiazole derivatives | ASTRAZENECA (SE) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106015-A1 | Novel use of benzothiazole derivatives | ITK, WEE2, WEE1 | ILK 1798/4885SSTR5 4632/4885HRH3 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.